IL-4Rα CRISPR Activation Plasmid (h): sc-418209-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IL-4Rα CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- IL-4Rα CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by IL-4Rα CRISPR Activation Plasmid (h) and IL-4Rα CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the IL4R transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IL-4Rα Antibody (H-4): sc-28361
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-4Rα CRISPR Activation Plasmid (h) | sc-418209-ACT | 20 µg | $397.00 |
Human IL4R encodes the interleukin-4 receptor alpha chain (IL-4Rα), a shared receptor subunit for IL-4 and IL-13 that shapes type 2 immune responses. Ligand engagement promotes receptor complex formation with IL2RG or IL13RA1 and activates JAK kinases with downstream STAT6 signaling, coordinating transcriptional programs involved in lymphocyte differentiation, IgE class switching, mucus production, and alternative macrophage polarization. IL-4Rα-dependent signaling intersects with PI3K/AKT and MAPK pathways to modulate cell survival and inflammatory tone across immune and epithelial compartments. Dysregulated IL4R activity is implicated in allergic inflammation and asthma biology, and has been associated with atopic phenotypes and immune microenvironment remodeling in cancer and other inflammatory settings.
IL-4Rα CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous IL4R expression without altering the underlying DNA sequence.
IL-4Rα CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the IL4R locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the IL4R transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous IL-4Rα expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native IL4R locus and enabling the study of IL-4Rα-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of IL-4Rα pathway restoration in tumor cells with silenced or reduced IL4R expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.